Clinical trials: Pulmonary Diseases
Cystic Fibrosis
Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study
Protocol 0000498: Multicenter, open label study to evaluate the effect of sustained RELiZORB (immobilized lipase) cartridge use during enteral feeding on fat absorption, as well as safety and tolerability of sustained RELiZORB…
- Trial name
- ASSURE (NCT02750501)
- Testing
- RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Alcresta Therapeutics, Inc.
COVID-19
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 3 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Trial name
- NCT05758519
- Testing
- QLS1128
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chronic Obstructive Pulmonary Disease
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.
- Trial name
- AERIFY-3 (NCT05326412)
- Testing
- Itepekimab SAR440340
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
Non Small Cell Lung Cancer, Healthy
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
- Trial name
- PROPHETIC (NCT05736029)
- Testing
- blood, stool and tissue samples collection
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- OncoHost Ltd.
COVID-19
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
The purpose of this study is to characterize descriptively the BNT162b2 vaccination safety experience among the Indonesian people.
- Trial name
- NCT05621239
- Testing
- BNT162b2
- Where
- Indonesia
- Volunteers
- 260 people
- Sponsor
- Pfizer
Advanced Non-Small Cell Lung Cancer
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.
- Trial name
- NCT03516981
- Testing
- Pembrolizumab, Favezelimab, Lenvatinib
- Where
- 81 sites in United States, Australia and 14 more
- Volunteers
- 245 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
A Study of S-892216 in Participants With COVID-19
The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT06928051
- Testing
- S-892216
- Where
- 57 sites in United States, Japan
- Volunteers
- 282 people
- Sponsor
- Shionogi
COVID-19
Validation of TERA Bio Station T101 of COVID-19 Tested Population.
TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19).
- Trial name
- NCT05088902
- Testing
- TERABio Ltd.
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tera Group
Non-Small Cell Lung Cancer
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
- Trial name
- NCT00633529
- Testing
- IMO-2055
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
- Trial name
- NCT06908772
- Testing
- Glumetinib Tablets, Osimertinib Mesylate Tablets
- Volunteers
- 390 people
- Sponsor
- Shanghai JMT-Bio Inc.
Asthma
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.
The purpose is to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in…
- Trial name
- NIMBUS (NCT01704495)
- Testing
- AZD5069
- Where
- 96 sites in Bulgaria, Canada and 11 more
- Volunteers
- 1,147 people
- Sponsor
- AstraZeneca
Asthma
Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid dependent Asthma.
- Trial name
- TROPOS (NCT02281357)
- Testing
- Tralokinumab
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine.
- Trial name
- NCT06291857
- Testing
- CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine
- Where
- 58 sites in Australia, New Zealand
- Volunteers
- 9,320 people, healthy volunteers welcome
- Sponsor
- Novavax
Lung Cancer
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy.
- Trial name
- NCT00538681
- Testing
- enzastaurin, pemetrexed, cisplatin
- Where
- 12 sites in Belgium, Germany and 3 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Respiratory Syncytial Virus Infections
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
- Trial name
- NCT07092865
- Testing
- Adjuvanted RSVPreF3 vaccine
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 168 people
- Sponsor
- GlaxoSmithKline
Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia
- Trial name
- NCT01808092
- Testing
- ceftazidim-avibactam (CAZ-AVI, experimental product), meropenem (active comparator)
- Where
- 123 sites in Argentina, Brazil and 24 more
- Volunteers
- 969 people
- Sponsor
- Pfizer
COVID-19
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
- Trial name
- NCT06878170
- Testing
- RBM-001
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rock BioMedical, Inc.
Pulmonary Disease, Chronic Obstructive
A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study is a 12-week, multicenter, randomized, double blind, parallel group, placebo-controlled study. The purpose of this study is to replicate the therapeutic benefit of UMEC/VI 62.5/25 microgram (mcg) on health-related…
- Trial name
- NCT02152605
- Testing
- UMEC/VI
- Where
- 54 sites in United States, Bulgaria and 5 more
- Volunteers
- 498 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.